|
Contact
Us
At
ShimodaAtlantic™, we're dedicated to researching pharmaceuticals
that will result in a positive difference in the outcome of cancer
therapy.
Our
focus is, however, primarily on research and development of new
therapies.
We do
not offer individualized patient treatment, advice, consultation or
therapy.
Our
clinical trials program is geared to getting drugs that merit further
investigation into the process of clinical evaluation.
Our
compassionate use program, once activated, will be limited to one drug,
Xenavex™, and we are presently unable to make that drug available
to any patient. We anticipate that we will be able to make the drug
available for compassionate use, upon specific, case-by-case FDA
approval, as a drug of last resort to certain types of cancer patients
who meet the stringent FDA criteria for access to investigational new
drugs.
Our
nanotherapy investigational new drug program is an early stage
development project. Due to the novel nature of nanotherapy, and the
unknown nature of the potential risks associated with nanoparticles, we
are surveying potential Phase I clinical trial candidates well in
advance of any potential trial, upon physician inquiry only.
If the
foregoing statements have not addressed your concerns or questions,
please feel free to contact us by telephone or email.
|
